1. Home
  2. SPRO vs CSBR Comparison

SPRO vs CSBR Comparison

Compare SPRO & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

71.6M

Sector

Health Care

ML Signal

HOLD

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

HOLD

Current Price

$5.02

Market Cap

81.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
CSBR
Founded
2013
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.6M
81.0M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
SPRO
CSBR
Price
$1.21
$5.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
607.0K
8.2K
Earning Date
05-13-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
$2,900,000.00
Revenue This Year
N/A
$4.84
Revenue Next Year
$300.00
$11.51
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.08
$4.83
52 Week High
$3.08
$8.74

Technical Indicators

Market Signals
Indicator
SPRO
CSBR
Relative Strength Index (RSI) 34.07 41.91
Support Level $1.18 $4.83
Resistance Level $1.29 $6.31
Average True Range (ATR) 0.05 0.25
MACD 0.03 0.02
Stochastic Oscillator 16.00 33.98

Price Performance

Historical Comparison
SPRO
CSBR

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Share on Social Networks: